Market Place
Sourcing Support
Amber Specialty Added to Pfizer’s Limited Distribution Network
03 Aug 2022 //
BUSINESSWIRE
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data
17 Sep 2020 //
BIOSPACE
Three FDA-approved drugs combat COVID in lung cells: report
05 Apr 2020 //
FIERCEBIOTECH
Pfizer Unveils +Ve Results for VIZIMPRO® as 1st line monotherapy in NSCLC
27 Nov 2019 //
BIOSPECTRUM ASIA
NICE shuts down AZ`s Tagrisso—and backs Pfizer rival Vizimpro instead
09 Jul 2019 //
FIERCE PHARMA
NICE OK for life-extending Vizimpro in lung cancer
06 Jul 2019 //
PHARMATIMES
Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal
18 Jun 2019 //
FIERCE PHARMA
Pfizer’s Vizimpro given go ahead be European Comission
12 Apr 2019 //
IN-PHARMATECHNOLOGIST
Pfizer`s tyrosine kinase inhibitor, Vizimpro gets European approval
04 Apr 2019 //
PHARMABIZ
VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU)
03 Apr 2019 //
PRESS RELEASE
Pfizer Receives Pos CHMP Opinion for Vizimpro/dacomitinib for NSCLC
04 Feb 2019 //
BUSINESSWIRE
EMA’s CHMP Recommends 6 New Meds, Releases Outcome of Sartan Investigation
01 Feb 2019 //
RAPS
FDA Drafts Guidance on Oncology Companion Diagnostics
08 Dec 2018 //
RAPS
Pfizer`s lung cancer drug gets FDA approval
28 Sep 2018 //
REUTERS
U.S. FDA Approves VIZIMPRO® (dacomitinib) for EGFR-Mutated Metastatic NSCLC
27 Sep 2018 //
BUSINESSWIRE
How Sensitive Is Pfizer To R&D Expense Changes?
04 Jul 2018 //
FORBES
Pfizer’s dacomitinib bests Iressa in NSCLC OS showdown
05 Jun 2018 //
FIERCE BIOTECH
Dacomitinib`s 7-Month Improvement in Overall Survival Advanced NSCLC
04 Jun 2018 //
BUSINESSWIRE
Pfizer files lung cancer drug in the EU, US
05 Apr 2018 //
PHARMA TIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.